Following the huge billion-dollar deals from the likes of Novartis, Eli Lilly, BMS, and AstraZeneca and the continued positive clinical momentum off the back of the Pluvicto approval, we are in the radiopharmaceutical renaissance. The immense medical and commercial potential in treating areas of unmet need in oncology is more apparent than ever with GlobalData reporting that venture capital deals in the space have grown by 550% to $408 million this year. FutureMarketInsights are projecting radiopharmaceutical uptake to reach $9.5 B by 2032. The field is charged with excited anticipation to what’s on the horizon!

As the space went nuclear, the 3rd Annual Targeted Radiopharmaceutical Summit US, industry’s number one radio-conjugate dedicated event of the year took place. With discussions on novel targets to decrease competition, radioisotope supply so your trial doesn’t get held up or combination or personalized therapies to know the best rationale for combos and maximize the therapeutic window - this was THE forum to learn from industry and ensure you maintained your competitive advantage from the rest of the crowd as we scoped the TRP landscape.

With a flurry of investment pouring into early-stage radiopharmaceutical companies and ongoing interest in theranostic and personalized medicine approaches, we united all the key pharma and biotech players in the space across Novartis, Bayer, AstraZeneca, Perspective Therapeutics, Telix Therapeutics, ARTBIO, OranoMed and many more. With players from early discovery, translational development, early and late stage clinical and supply chain, alongside the clinician’s perspective, we were treated to a one-stop shop on all the radiopharmaceuticals.

Meeting both your business and scientific needs in one place, in 2024 we introduced brand new tracks dedicated to early stage and late-stage clinical development and even more networking opportunities for those dedicated to business development.

Driven by the shared commitment within the TRP community to address the ongoing unmet needs in oncology, this year's meeting was the most significant and impactful iteration yet.